- Home
- SNGX vs SNOA Comparison
SNGX vs SNOA Comparison
Compare SNGX & SNOA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNGX
- SNOA
- Stock Information
- Founded
- SNGX 1987
- SNOA 1999
- Country
- SNGX United States
- SNOA United States
- Employees
- SNGX N/A
- SNOA N/A
- Industry
- SNGX Biotechnology: Pharmaceutical Preparations
- SNOA Biotechnology: Pharmaceutical Preparations
- Sector
- SNGX Health Care
- SNOA Health Care
- Exchange
- SNGX Nasdaq
- SNOA Nasdaq
- Market Cap
- SNGX 6.5M
- SNOA 6.4M
- IPO Year
- SNGX 1987
- SNOA 2007
- Fundamental
- Price
- SNGX $1.89
- SNOA $3.47
- Analyst Decision
- SNGX
- SNOA
- Analyst Count
- SNGX 0
- SNOA 0
- Target Price
- SNGX N/A
- SNOA N/A
- AVG Volume (30 Days)
- SNGX 18.7K
- SNOA 70.1K
- Earning Date
- SNGX 05-09-2025
- SNOA 06-16-2025
- Dividend Yield
- SNGX N/A
- SNOA N/A
- EPS Growth
- SNGX N/A
- SNOA N/A
- EPS
- SNGX N/A
- SNOA N/A
- Revenue
- SNGX $2,342.00
- SNOA $13,973,000.00
- Revenue This Year
- SNGX N/A
- SNOA $23.89
- Revenue Next Year
- SNGX N/A
- SNOA $25.45
- P/E Ratio
- SNGX N/A
- SNOA N/A
- Revenue Growth
- SNGX N/A
- SNOA 13.51
- 52 Week Low
- SNGX $1.68
- SNOA $1.75
- 52 Week High
- SNGX $14.83
- SNOA $9.37
- Technical
- Relative Strength Index (RSI)
- SNGX 45.39
- SNOA 59.16
- Support Level
- SNGX $1.85
- SNOA $3.05
- Resistance Level
- SNGX $1.95
- SNOA $3.41
- Average True Range (ATR)
- SNGX 0.09
- SNOA 0.20
- MACD
- SNGX 0.01
- SNOA -0.00
- Stochastic Oscillator
- SNGX 42.11
- SNOA 79.31
About SNGX Soligenix Inc.
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).
About SNOA Sonoma Pharmaceuticals Inc.
Sonoma Pharmaceuticals Inc is a specialty pharmaceutical company operating in the United States. It is engaged in identifying, developing, and commercializing differentiated therapies for patients living with chronic skin conditions. The company focuses on the development and commercialization of therapeutic solutions in medical dermatology to treat skin conditions, such as acne, atopic dermatitis, and scarring. The key products of the company are Celacyn, Ceramax Skin Barrier Cream, Mondoxyne, Alevicyn, SebuDerm, Microcyn, and Microcyn which are available for various skin treatments such as scars, itchy skin, minor skin irritations, rashes, and others. The company derives revenue from the sale of products in the United States, Latin America, Europe, Asia, and other countries.